UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells

PURPOSE: This study aimed to investigate the possibility of UCP-2 inhibitor in reducing acquired resistance of trastuzumab to improve the outcome of patients receiving trastuzumab therapy by exploring the relationship between UCP-2 expression and HER2 signaling pathway and examining whether UCP-2 ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Jun, Zhang, Zhe, Zhang, Lili, Sun, Yan, Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367901/
https://www.ncbi.nlm.nih.gov/pubmed/34146128
http://dx.doi.org/10.1007/s00280-021-04303-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367901/
https://www.ncbi.nlm.nih.gov/pubmed/34146128
http://dx.doi.org/10.1007/s00280-021-04303-4

Ejemplares similares